• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Psybio Therapeutics Corp (OP: PSYBF )

    0.0085 UNCHANGED
    Streaming Delayed Price Updated: 3:47 PM EDT, Jun 13, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 0.0085
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 0.0085
    Today's Range 0.0085 - 0.0085
    52wk Range 0.0030 - 0.0267
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    MA, FL And OH Psychedelics Scientists And Educators' Latest Research And Views
    Along with a growing scientific corpus supporting the therapeutic potential of psychedelics, several states and most noticeably Massachusetts are seeing the decriminalization of natural substances... 
    Via Benzinga
    EXCLUSIVE: Reinventing Mental Health & Next-Gen Psychedelics, 'Access And Clinical Data Are Key'
    Experts gathered at the Benzinga Psychedelics Capital Conference in Miami Beach on Thursday where they talked about revolutionizing psychedelic therapy as a promising new approach for treating mental... 
    Via Benzinga

    Performance

    YTD
    +66.67%
    +66.67%
    1 Month
    +39.34%
    +39.34%
    3 Month
    +107.32%
    +107.32%
    6 Month
    +112.50%
    +112.50%
    1 Year
    -55.96%
    -55.96%

    More News

    Read More
    Psyched: Psychedelic Therapy In The Workplace, UCL's Brain Imaging Study, COMPASS Trials And More
    Via Benzinga
    Psychedelics & Environmental Protection: Company Seeks Patents To Synthetically Produce Toad Venom
    Via Benzinga
    Psychedelics Production Methods Expect Further IP Protection With 4 New Patents
    Via Benzinga
    Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project
    Via Benzinga
    PsyBio Therapeutics Reports Interim Third Quarter 2022 Financial Results
    Via Benzinga
    Yeast Produces Bread And Psilocybin, This Company Is Moving Into Clinical Trial Phase
    Via Benzinga
    Most, But Not All, Psychedelics Companies Have Sufficient Liquidity
    Via Benzinga
    DMT Producer PsyBio And Shrooms Grower Red Light Holland Share Their Most Recent Financial Results
    Via Benzinga
    PsyBio Therapeutics Presents "How Genetically Modified Bacteria Can Yield Best-In-Class Psychedelics" At The Psychedelic Capital Conference
    Via Benzinga
    Cannabis Movers & Shakers: Burns & Levinson, Water Ways, Chill Brands, Rubicon Organics
    Via Benzinga
    Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
    Via Benzinga
    There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
    Via Benzinga
    Psyched: Delic Buys 10 Ketamine Clinics For $10M, Atai Launches Ibogaine Human Trials, Small Pharma Concludes Phase 1 DMT Study
    Via Benzinga
    Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies
    Via Benzinga
    Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.